A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, administered intravenously (IV) in monotherapy (Arm 1) or combination with BMS-986405 (Arm 2), to determine the maximum tolerated dose (MTD) of CC-99712 guided by a Bayesian logistic regression model (BLRM). A modified accelerated titration design will also be used for Arm 1 and Arm 2. The MTD may be established separately for CC-99712 administered at Q3W and/ or Q4W schedules. The expansion part (Part B) will further evaluate the safety and efficacy of CC-99712 in monotherapy (Arm 1) or combination (Arm 2) administered at or below the MTD in selected expansion cohorts in order to determine the RP2D. One or more doses or dosing regimens may be selected for cohort expansion. All participants will be treated until confirmed disease progression per IMWG criteria, unacceptable toxicity, or participants//Investigator decision to withdraw.

Key facts

Study ID

NCT04036461

Run by

Celgene

People needed

47

Starts

2019-08-26

Expected to finish

2024-08-19

Last updated by the study team

2024-08-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Participant has symptomatic central nervous system involvement of MM.
• Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.
• Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.
• Subject is a pregnant or lactating female.
• Subject has known human immunodeficiency virus (HIV) infection.
• Subject has active hepatitis B or C (HBV/HCV) infection.
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 107 — La Jolla, California, United States
• Local Institution - 105 — Sarasota, Florida, United States
• Local Institution - 103 — Buffalo, New York, United States
• Local Institution - 106 — New York, New York, United States
• Local Institution - 101 — Portland, Oregon, United States
• Local Institution - 104 — Dallas, Texas, United States
• Local Institution - 102 — Seattle, Washington, United States
• Local Institution - 202 — Toronto, Ontario, Canada
• Local Institution - 201 — Montreal, Quebec, Canada
• Institut Paoli Calmettes — Marseille, France
• CHU Montpellier - Hôpital Saint Eloi — Montpellier, France
• Hopital Saint Antoine — Paris, France
• Local Institution - 305 — Pierre-Bénite, France
• Local Institution - 501 — Bologna, Italy
• Local Institution - 405 — Barcelona, Spain
• Local Institution - 401 — Madrid, Spain
• Local Institution - 0505 — Málaga, Spain
• Local Institution - 402 — Salamanca, Spain
• Local Institution - 404 — Sevillla, Spain
• Local Institution - 403 — Valencia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.